RU2010109358A - Твердые лекарственные формы с контролируемым высвобождением, содержащие азитромицин - Google Patents

Твердые лекарственные формы с контролируемым высвобождением, содержащие азитромицин Download PDF

Info

Publication number
RU2010109358A
RU2010109358A RU2010109358/15A RU2010109358A RU2010109358A RU 2010109358 A RU2010109358 A RU 2010109358A RU 2010109358/15 A RU2010109358/15 A RU 2010109358/15A RU 2010109358 A RU2010109358 A RU 2010109358A RU 2010109358 A RU2010109358 A RU 2010109358A
Authority
RU
Russia
Prior art keywords
dosage form
controlled release
azithromycin
oral administration
solid
Prior art date
Application number
RU2010109358/15A
Other languages
English (en)
Russian (ru)
Inventor
Радхакришнан ПИЛЛАЙ (US)
Радхакришнан ПИЛЛАЙ
Прамод САРПОТДАР (US)
Прамод САРПОТДАР
Дэвид В. ОСБОРН (US)
Дэвид В. ОСБОРН
Гордон Дж. ДОУ (US)
Гордон Дж. ДОУ
Original Assignee
Доу Фармасьютикал Сайенсиз, Инк. (Us)
Доу Фармасьютикал Сайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Доу Фармасьютикал Сайенсиз, Инк. (Us), Доу Фармасьютикал Сайенсиз, Инк. filed Critical Доу Фармасьютикал Сайенсиз, Инк. (Us)
Publication of RU2010109358A publication Critical patent/RU2010109358A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2010109358/15A 2007-09-05 2008-07-30 Твердые лекарственные формы с контролируемым высвобождением, содержащие азитромицин RU2010109358A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96750407P 2007-09-05 2007-09-05
US60/967,504 2007-09-05
US12/002,417 2007-12-17
US12/002,417 US8124123B2 (en) 2007-09-05 2007-12-17 Controlled release azithromycin solid dosages forms

Publications (1)

Publication Number Publication Date
RU2010109358A true RU2010109358A (ru) 2011-10-20

Family

ID=40407900

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010109358/15A RU2010109358A (ru) 2007-09-05 2008-07-30 Твердые лекарственные формы с контролируемым высвобождением, содержащие азитромицин
RU2010109359/15A RU2010109359A (ru) 2007-09-05 2008-09-04 Азитромицин для лечения кожных заболеваний

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2010109359/15A RU2010109359A (ru) 2007-09-05 2008-09-04 Азитромицин для лечения кожных заболеваний

Country Status (12)

Country Link
US (2) US8124123B2 (enExample)
EP (2) EP2197420A4 (enExample)
JP (2) JP2010538062A (enExample)
KR (2) KR20100063088A (enExample)
CN (2) CN101861138A (enExample)
AR (1) AR068368A1 (enExample)
AU (2) AU2008295579A1 (enExample)
BR (1) BRPI0816268A2 (enExample)
CA (2) CA2697496A1 (enExample)
RU (2) RU2010109358A (enExample)
WO (2) WO2009032037A1 (enExample)
ZA (2) ZA201001649B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553136T3 (es) 2002-12-13 2015-12-04 Durect Corporation Sistema de administración oral de fármacos que comprende materiales vehículos líquidos de alta viscosidad
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
WO2018009566A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
NZ792518A (en) * 2016-10-06 2023-04-28 Orbus Therapeutics Inc Formulations for administration of eflornithine
CN109875970B (zh) * 2019-01-08 2021-08-06 石家庄四药有限公司 阿奇霉素固体制剂及其制备方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US6068859A (en) * 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
AU2004267909B2 (en) * 2003-08-29 2008-12-18 Veloxis Pharmaceuticals, Inc. Modified release compositions comprising tacrolimus
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
EP1830815A1 (en) 2004-12-21 2007-09-12 Pfizer Products Incorporated Enteric coated azithromycin multiparticulates
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
EP2074992B1 (en) * 2005-04-08 2015-05-20 Abbott Laboratories Oral pharmaceutical formulations comprising salts of fenofibric acid
CA2626551A1 (en) * 2005-11-09 2007-08-02 Dow Pharmaceutical Sciences Azithromycin for treatment of granulomatous rosacea
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne

Also Published As

Publication number Publication date
US20120121702A1 (en) 2012-05-17
JP2010538066A (ja) 2010-12-09
CN101835475A (zh) 2010-09-15
BRPI0816268A2 (pt) 2017-08-22
CA2697537A1 (en) 2009-03-12
WO2009032268A1 (en) 2009-03-12
EP2197420A1 (en) 2010-06-23
ZA201001705B (en) 2010-12-29
WO2009032037A1 (en) 2009-03-12
EP2197453A1 (en) 2010-06-23
US8124123B2 (en) 2012-02-28
ZA201001649B (en) 2010-11-24
CA2697496A1 (en) 2009-03-12
AU2008295579A1 (en) 2009-03-12
AU2008296903A1 (en) 2009-03-12
AR068368A1 (es) 2009-11-11
KR20100054842A (ko) 2010-05-25
EP2197453A4 (en) 2010-10-20
JP2010538062A (ja) 2010-12-09
KR20100063088A (ko) 2010-06-10
CN101861138A (zh) 2010-10-13
US20090060994A1 (en) 2009-03-05
EP2197420A4 (en) 2010-10-20
RU2010109359A (ru) 2011-10-20

Similar Documents

Publication Publication Date Title
RU2010109358A (ru) Твердые лекарственные формы с контролируемым высвобождением, содержащие азитромицин
US8277843B2 (en) Programmable buoyant delivery technology
CN102579387A (zh) 包含s1p调节剂的药物组合物
TW202237126A (zh) Janus激酶(jak)抑制劑的延遲緩釋口服藥物劑型及其使用方法
NO20071044L (no) Doseformer med enteraltbelagte tablettkjerner
HRP20240045T1 (hr) Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta
CN103228676A (zh) 羟烷基纤维素
JP2010538062A5 (enExample)
KR20160030383A (ko) 오메가-3 지방산 에스테르 및 스타틴계 약물을 포함하는 경구용 복합제제
US20150224060A1 (en) Gastric retentive tablet compositions
KR102283582B1 (ko) 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
WO2006040779A3 (en) Controlled release gastric floating matrix formulation containing imatinib
TR201616998A1 (en) DELAYED RELEASE DOSING FORMS WITH DIMETHYL FUMARATE
KR20180135020A (ko) 니코틴아미드의 경구 약제학적 조성물
AU2016231883A1 (en) Pharmaceutical compositions of dimethyl fumarate
TWI415632B (zh) It has the function of correctly dividing the dosage function
JP2017048174A (ja) 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤
GR1009149B (el) Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων
WO2015108392A1 (ko) 에스오메프라졸 함유 소형 의약정제
CN105025883A (zh) 右哌甲酯或其盐的调节释放的药物组合物
ES2755075T3 (es) Forma farmacológica para la liberación dirigida de principios activos
JP6866136B2 (ja) デュロキセチン塩酸塩を含む口腔内崩壊錠
CN103040785A (zh) 一种渗透胃滞留片及其制备方法
CN101590040A (zh) 含有吲哒帕胺和b族维生素的组合物及其用途
RU2008137778A (ru) Лекарственная форма с модифицированным высвобождением 6-метил-2-этил-3-гидроксипиридина сукцината